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Aminaphtone, a drug used in the treatment of chronic venous insufﬁciency (CVI), showed a remarkable
role in the modulation of several vasoactive factors, like endothelin-1 and adhesion molecules. We
analysed in vitro the effects of Aminaphtone on whole-genome gene expression and production of dif-
ferent inﬂammatory proteins. ECV-304 endothelial cells were stimulated with IL-1β 100 U/ml in the
presence or absence of Aminaphtone 6 μg/ml. Gene expression proﬁles were compared at 1, 3, and 6 h
after stimulation by microarray. Supernatants of ECV-304 cultures were analysed at 3, 6, 12, and 24 h by
multiplex ELISA for production of several cytokine and chemokines. Microarrays showed a signiﬁcant
down-regulation at all times of a wide range of inﬂammatory genes. Aminaphtone appeared also able to
modulate the regulation of immune response process (down-regulating cytokine biosynthesis, tran-
scripts involved in lymphocyte differentiation and cell proliferation, and cytokine-cytokine receptor
interaction) and to regulate genes engaged in homeostasis, secretion, body ﬂuid levels, response to
hypoxia, cell division, and cell-to-cell communication and signalling. Results were conﬁrmed and ex-
tended analysing the secretome, which showed signiﬁcant reduction of the release of 14 cytokines and
chemokines. These effects are predicted to be mediated by interaction with different transcription fac-
tors.
Aminaphtone was able to modulate the expression of inﬂammatory molecules relevant to the pa-
thogenesis of several conditions in which the endothelial dysfunction is the main player and early event,
like scleroderma, lung ﬁbrosis, or atherosclerosis.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Aminaphtone (C18-H15-N-O4) is a synthetic molecule derived
from 4-aminobenzoic acid, which is currently employed in the
management of capillary disorders. The drug has been used both
to treat and prevent late complications of patients affected by
chronic venous insufﬁciency (CVI) of the lower limbs, efﬁciently
reducing vessel permeability and the number and size of leg ulcers
(Doni et al., 1983; Smith, 2001; Villaverde et al., 1989). It has been
suggested that Aminaphtone increases capillary resistance by ther B.V. This is an open access article
sufﬁciency; ECs, endothelial
rtension; TFs, transcription
ondazione IRCCS Ca’ Granda
no, Italy.inhibition of hyaluronidases, and a few published case reports
showed that the drug is effective in reducing oedema in idiopathic
cyclic oedema (Pereira de Godoy, 2008) and ameliorating purpuric
lesions in Schamberg’s disease (de Godoy and Batigalia, 2009).
Despite this, little is known about the effects of Aminaphtone at
molecular level.
Previous works from our group investigated whether Ami-
naphtone down-regulates molecules with key vasoactive roles.
First, we examined whether Aminaphtone modulates the expres-
sion of the vasoconstrictive molecule endothelin-1 in endothelial
cells (ECs). Endothelin-1 is involved in CVI pathogenesis, as pro-
longed venous stasis and hypoxia-induced vasoconstriction de-
termine ischemia with consequent smooth muscle cell activation,
decrement of nitric oxide (NO), and overexpression of endothelin-
1, which in turn exacerbates ischemia. We demonstrated that
Aminaphtone was able to decrease endothelin-1, both at mRNA
and protein level, in ECV304 EC-line stimulated with IL-1β, in aunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Given the involvement of endothelin-1 in the pathogenesis of
Pulmonary Arterial Hypertension (PAH) (Giaid et al., 1993), we
studied the action of Aminaphtone in vivo in a rat model of
monocrotaline-induced PAH (Zambelli et al., 2011). Aminaphtone
at the highest dose reduced plasma concentration of endothelin-1,
attenuated right ventricular hypertrophy, and lessened the wall
thickness of the pulmonary arteries, which are a direct morpho-
logical consequence of high levels of endothelin-1.
Furthermore, we analysed the inﬂuence of Aminaphtone on the
regulation of adhesion molecules in vivo. In a 12-week prospective,
randomized, open-label pilot study on 24 patients with Systemic
Sclerosis, of whom 12 were controls and 12 were treated with
Aminaphtone 75 mg ter in die, we observed a decrease in the
concentrations of circulating soluble adhesion molecules. The ef-
fect of Aminaphtone appeared to be preferentially exerted on so-
luble endothelium leukocyte adhesion molecule 1 (sELAM-1) and
vascular cell adhesion molecule 1 (sVCAM-1) (Scorza et al., 2008b).
In this work, we seek to explore the actions of Aminaphtone at
the molecular level. In particular, we focused our attention on
whether it favourably modulates inﬂammatory pathways. To this
end, we used the microarray technology to investigate the global
gene expression proﬁle and its modulation over time in a human
EC model subjected to an inﬂammatory stimulus and/or treatment
with Aminaphtone. We then conﬁrmed and extended our ob-
servation at post-transcriptional level, by quantifying different
pro-inﬂammatory mediators in cell culture supernatants using
multiplex bead-based and singleplex ELISA techniques.2. Materials and methods
2.1. Cell culture and treatments
Human ECV304 endothelial cells (ECACC No. 92091712) were
grown in M199 medium (Invitrogen, Carlsbad, CA) supplemented
with 10% foetal bovine serum (FBS; Hyclone, Logan, UT), 50 U/ml
penicillin, and 50 U/ml streptomycin in a 37 °C humidiﬁed in-
cubator with 5% CO2. Cells were seeded at 4105/well in 6-well
tissue-culture treated plates. Twenty‐four h before treatment,
cells were serum starved (1% FBS) in order to synchronize the
mitotic phase.
Aminaphtone was generously gifted by Baldacci S. p. A., Pisa,
Italy. The lyophilized drug was ﬁrst diluted with dimethyl sulf-
oxide (Sigma-Aldrich, St. Louis, MO), and then 1:10 with Dulbec-
co's phosphate buffered saline without calcium and magnesium to
a concentration of 0.1 mg/ml. This solution was further diluted
with complete M199 to a 6 μg/ml ﬁnal concentration, which
roughly corresponds to the drug peak plasma concentration that
can be observed in healthy subjects after an oral administration of
Aminaphtone 75 mg (Scorza et al., 2008b).
Conﬂuent ECV304 cells were incubated for 1, 3, 6, 12, and 24 h
with recombinant interleukin-1β (IL-1β; Sigma-Aldrich) 100 IU/ml
in the presence of Aminaphtone 6 μg/ml or an equal volume of
medium alone. All experiments were performed in two separate
series of three independent replicates for each time point. Gene
expression analysis was performed at 1, 3, and 6 h-time points;
protein detection in the supernatants was executed at 3, 6, 12, and
24 h.
2.2. RNA extraction
Total RNA extraction was performed using the TRIzol Reagent
(Life Technologies, Rockville, MD) directly added to the EC culture
plates after 1, 3, and 6-h treatment, following the manufacturer's
protocol. Genomic DNA contamination was eliminated treatingRNA samples with RNase-free Turbo DNase (Life Technologies) for
15 min at room temperature. RNA quantity and purity were eval-
uated using an Inﬁnite 200 PRO plate reader (Tecan, Männedorf,
Switzerland) for micro-volume spectrophotometry; quality and
integrity were checked by the RNA 6000 Nano kit with a Bioana-
lyzer 2100 (Agilent Technologies, Santa Clara, CA). The ratio of
absorbance at 260 and 280 nm was Z1.9 and the RNA integrity
number (RIN) was 48 for all samples.
2.3. Whole-genome gene expression analysis
The RNA samples from the ﬁrst experimental series of three
independent replicates, collected at 1, 3, and 6 h after treatment,
were used for gene expression proﬁling. Preparation of DNA sin-
gle-stranded sense target, hybridization to GeneChip Gene 1.0 ST
Arrays (Affymetrix, Santa Clara, CA), and scanning of the chips on
an Affymetrix 7G Scanner were carried out according to manu-
facturer's protocols.
The RMAExpress software version 1.0.5 was used for back-
ground adjustment, quantile normalization, and probe set sum-
marization by the Robust Multi-array Average (RMA) procedure
(Bolstad et al., 2003; Irizarry et al., 2003). Probe sets mapping on
the same gene were considered as single series of expression value
by means of the median polish summarization algorithm. Gene
ﬁltering and annotation were performed using BRB-ArrayTools
version 4.3.2 developed by Dr. Richard Simon and BRB-ArrayTools
Development Team and R packages available from Bioconductor
release 2.12 (Gentleman et al., 2004). Probe sets with a mean in-
tensity less than 10 in at least one time point in one of the treat-
ment class (corresponding to a low but robust expression level)
were ﬁltered out. Genes showing minimal variation across the
samples, i.e. with a P-value of the log-ratio variation greater than
0.01, were deemed as non-informative and excluded from further
analysis. Multiple probe sets were reduced to one per gene symbol
by using the most variable probe set measured by interquartile
range across arrays. Project was annotated by Bioconductor an-
notation package hugene10sttranscriptcluster.db version 8.0.1.
Differentially expressed genes were identiﬁed combining two
different approaches, using algorithms incorporated in the open-
source software MultiExperiment Viewer (MeV) version 4.9 (Saeed
et al., 2003). First we used the Bayesian Estimation of Temporal
Regulation (BETR) method (Aryee et al., 2009), to identify genes
that vary signiﬁcantly between the two conditions across time
points. BETR is a linear random-effect modelling framework that
takes into account correlations within samples between sampling
times. Genes assigned an alpha value less than 0.1, i.e. an accep-
table False Discovery Rate (FDR)o10%, were deemed signiﬁcantly
different. Then, given the balanced factorial design of the study,
we used a two-factor ANOVA to determine which genes were
mainly inﬂuenced by the treatment effect per se (Aminaphtone)
and/or by the interaction effect of the two factors (time and
treatment). Genes were considered statistically signiﬁcant if the P-
values (for treatment and/or interaction), computed from the
F-distribution, were less than 0.05. This was followed by pairwise
comparisons to identify signiﬁcantly different gene expression at
alpha less than 0.05 (Student's 2-tailed t-test) between treatment
classes at any time points.
Hierarchical cluster analysis was performed to visualize the
similarity and differences in gene expression proﬁles among the
samples, using the algorithm implemented in BRB-ArrayTools.
Log2 transformed normalized gene expression values were med-
ian-centred and scaled and clustered by Pearson's centred corre-
lation and average linkage.
We then used a clustering algorithm called CLICK (CLuster
Identiﬁcation via Connectivity Kernels), implemented in the java-
based tool EXPression ANalyzer and DisplayER (EXPANDER) v6.3
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with distinct temporal patterns between the two conditions. CLICK
makes use of graph-theoretic and statistical techniques to re-
cognize tight groups of highly similar elements. We used the al-
gorithm with the default homogeneity parameter ¼0.65 for a
balanced intra-cluster similarity and inter-cluster separation.
Functional analysis on the entire dataset of signiﬁcant genes
identiﬁed by BETR was performed by examining gene sets for
differential expression among the treatment classes. The gene sets
were deﬁned based on Gene Ontology (GO) terms (http://www.
geneontology.org) (The Gene Ontology Consortium, 2015), the
Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway da-
tabase (http://www.genome.jp/kegg/pathway.html), and the
Broad Institute Molecular Signature Database (MsigDB; curated
gene sets) (Subramanian et al., 2005). To ﬁnd signiﬁcant gene sets
we used the LS/KS permutation tests, which ﬁnd gene sets with
more genes differentially expressed among the phenotype classes
than expected by chance. The threshold for determining sig-
niﬁcant gene sets was P-value lower than 0.005. Redundant GO
terms were removed using the web-based tool REViGO (Supek
et al., 2011), with an allowed similarity threshold of 0.5. Not per-
tinent gene sets were manually removed.
Functional analysis of the gene clusters identiﬁed by CLICK was
carried out using the TANGO (Tool for ANalysis of GO enrichments)
algorithm implemented in EXPANDER, which performs hyper-
geometric enrichment tests on GO terms and corrects for multiple
testing by bootstrapping (1000 bootstraps), thus estimating the
empirical P-value distribution for the evaluated sets. A functional
class was considered signiﬁcantly enriched in a cluster of co-
regulated genes (as detected above) if its corrected P-value was
lower than 0.05. Similarly, we conducted a KEGG pathway en-
richment analysis by hyper-geometric enrichment tests, correcting
for multiple testing using the Bonferroni correction.
Finally, using the PRIMA (PRomoter Integration in Microarray
Analysis) algorithm, we identiﬁed transcription factors (TFs)
whose binding sites are signiﬁcantly over-represented in theTable 1
Top 25 differentially expressed genes in Aminaphtone-treated vs. untreated IL-1β stimu
Symbol Name FD
BNIP3 BCL2/adenovirus E1B 19 kDa interacting protein 3 o110
CCL22 chemokine (C-C motif) ligand 22 o110
EBI3 Epstein-Barr virus induced 3 o110
EDN1 endothelin 1 o110
HIST2H4A histone cluster 2, H4a o110
IGFL1 IGF-like family member 1 o110
MMP10 matrix metallopeptidase 10 (stromelysin 2) o110
MYLIP myosin regulatory light chain interacting protein o110
PFKFB4 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 o110
PRDM1 PR domain containing 1, with ZNF domain o110
S100A3 S100 calcium binding protein A3 o110
TNFSF18 tumor necrosis factor (ligand) superfamily, member 18 o110
CNNM4 cyclin M4 o110
EVA1A eva-1 homolog A (C. elegans) o110
HK2 hexokinase 2 o110
PDK1 pyruvate dehydrogenase kinase, isozyme 1 o110
FOS FBJ murine osteosarcoma viral oncogene homolog o110
TNFRSF11B tumor necrosis factor receptor superfamily, member 11b o110
PLCB4 phospholipase C, beta 4 o110
TGFB2 transforming growth factor, beta 2 o110
MMP3 matrix metallopeptidase 3 (stromelysin 1, progelatinase) o110
CYP24A1 cytochrome P450, family 24, subfamily A, polypeptide 1 o110
DKK1 dickkopf 1 homolog (Xenopus laevis) o110
ELMSAN1 ELM2 and Myb/SANT-like domain containing 1 o110
KCTD11 potassium channel tetramerisation domain containing 11 o110
FDR: P-values corrected for the false discovery rate, at the BETR analysis. Ptreatm: P-valu
time and treatment, at two-factor ANOVA. Ppairw: signiﬁcance level for post-hoc pairwispromoters of genes within each cluster pointed out by CLICK. A TF
binding site was considered signiﬁcantly enriched in a cluster if its
P-value was lower than 5104. The gene sets were deﬁned
based on experimentally determined TF binding sites derived from
the TRANSFAC Database (http://www.gene-regulation.com)
(Wingender, 2008).
2.4. Reverse transcription quantitative-PCR validation
The same RNA samples used for microarray proﬁling, together
with a second series of three independent replicates, were used for
PCR validation. First-strand complementary DNA (cDNA) for single
target gene expression analysis was synthesized from 3 μg of total
RNA for each sample using the High Capacity cDNA Reverse
Transcription Kit (Life Technologies). Expression of CSF3, IGFL1,
TGFB2, TNF, TNFRSF11B, TNFSF18 (cf. Table 1 in Ref. Salazar et al.,
submitted for publication, for gene names), and the endogenous
control genes β-actin (ACTB), glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH), and hypoxanthine guanine phosphoribosyl
transferase 1 (HPRT1) was measured by reverse transcription (RT)
quantitative-PCR (RT-qPCR) using single TaqMan Gene Expression
Assays run on the Vii7A real-time PCR System (Life Technologies).
TaqMan Gene Expression Master Mix and cDNA sample (20 ng/
well) were handled with a MICROLAB STAR robotic station (Ha-
milton Robotics, Bonaduz, Switzerland), to standardize liquid
handling and minimize manual error. Three replicates of each gene
for each sample were run in a 384-well format plate. The following
TaqMan-based assays were used: Hs00357085_g1 (CSF3),
Hs01651089 (IGFL1), Hs00234244_m1 (TGFB2), Hs00900358_m1
(TNFRSF11B), Hs00183225_m1 (TNFSF18), Hs01060665_g1 (ACTB),
Hs02758991_g1 (GAPDH), and Hs99999909_m1 (HPRT1) (all from
Life Technologies), and Hs. PT.56a.41006330 (TNF-α) (Integrated
DNA Technologies, Coralville, IA). Experimental threshold and
baseline were calculated by the algorithm of the Vii7A RUO Soft-
ware v1.2 (Life Technologies), and data were analysed by the cor-
rected ΔΔCt method (Pfafﬂ, 2001).lated endothelial cells, according to BETR analysis.
Fold-change Ppairw
R Ptreatm Pinteract 1 h 3 h 6 h 1 h 3 h 6 h
7 o1104 o1105 1.1 1.1 2.5 b
7 o1105 ns 1.4 2.2 2.0 a b b
7 o1105 ns 1.8 1.7 2.1 b b b
7 o1105 ns 1.8 1.9 2.0 b b b
7 o1106 o0.05 1.9 1.5 1.3 b b b
7 o1104 ns 2.1 2.0 2.4 b b b
7 o0.001 o0.01 1.0 1.4 2.4 a b
7 o1106 o1104 2.8 1.5 1.1 b b
7 o0.001 o1104 1.1 1.0 2.7 b
7 o1104 o1105 2.5 1.0 1.0 b
7 o1105 ns 2.4 1.4 2.0 b b
7 o1105 ns 2.4 4.2 3.4 b b b
6 o1104 o0.001 1.1 2.0 1.6 b b
5 o1106 o0.01 1.2 1.5 1.7 a b b
5 o0.001 o0.01 1.1 1.4 2.3 a b
5 o0.05 o0.001 1.4 1.2 2.4 a b
5 o0.001 o0.001 2.1 1.0 1.1 b
5 o0.001 ns 1.5 2.6 1.7 b a
5 o0.05 o0.01 1.7 2.1 2.1 a b b
4 o0.01 o0.01 1.2 2.1 1.5 b a
4 o0.01 o0.05 1.0 1.6 2.6 a b
4 o1104 ns 1.5 1.7 1.5 b b b
4 o1104 o0.05 1.2 1.2 1.9 b
4 o0.05 o1104 1.9 1.2 1.1 b a
4 o0.001 ns 1.9 1.4 1.7 b b
es for the treatment effect; and Pinteract: P-values for the interaction effect between
e comparisons: a Po0.05; b Po0.01.
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the mean intensity of the three most stable endogenous control
genes (ACTB, GAPDH, and HPRT1) selected from a set of eight (the
aforementioned plus β-2-microglobulin, phosphoglycerate kinase
1, pumilio homolog 1, ribosomal protein large P0, secretogranin V,
and tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein zeta polypeptide). Analysis of gene expression
stability and selection of the best reference genes were performed
using the NormFinder version 0.953 Excel Add-In (Andersen et al.,
2004) on the RMA expression values.
2.5. Cytokine measurement in the secretome
Supernatants were collected at 3, 6, 12, and 24 h after treat-
ment with IL-1β with or without Aminaphtone. All samples were
from the same two series used for gene expression analysis, which
included three independent experiments each. The concentrations
of 30 cytokines/chemokines were measured by bead based mul-
tiplexing technique, using the Human Cytokine Magnetic 30-plex
Panel Assay (Life Technologies) according to the manufacturer's
protocol. Namely, the cytokines tested were: IL-1β, IL-1 receptor α
(IL-1RA), IL-2, IL-2 receptor (IL-2R), IL-4, IL-5, IL-6, IL-7, IL-8, IL-10,
IL-13, IL-15, IL-17, basic ﬁbroblast growth factor (FGF-basic), epi-
dermal growth factor (EGF), EOTAXIN, hepatocyte growth factor
(HGF), granulocyte colony-stimulating factor (G-CSF), granulocyte-
macrophage colony-stimulating factor (GM-CSF), interferon-alpha
(IFN-α), interferon-gamma (IFN-γ), interferon gamma-induced
protein 10 (IP-10) macrophage inﬂammatory protein-1-alpha
(MIP-1α), macrophage inﬂammatory protein-1-beta (MIP-1β),
macrophage migration inhibitory factor (MIF), monocyte chemo-
tactic protein-1 (MCP-1), monokine induced by gamma interferon
(MIG), RANTES, tumor necrosis factor-alpha (TNF-α), vascular en-
dothelial growth factor (VEGF). Analyte readings were taken in a
Bio-Plex 2200 reader and calculated using the software Bio-Plex
Manager version 6.0 (Bio-Rad Laboratories, Hercules, CA). Assay
sensitivity was 45 pg/ml for each analyte. Signal quantiﬁcation
was based on standard bead curves run in parallel to the test,
using nonlinear 5-parameter logistic equations when ﬁtting data
points.
Production of CXCL-6, IGF-1, and TGF-β2 was quantiﬁed by
ELISA (R&D Systems, Minneapolis, MN), according to the manu-
facturer's instructions. This immunometric assay is based on a
quantitative sandwich enzyme immunoassay technique.
2.6. Statistical analysis
The software GraphPad Prism version 5.03 (GraphPad Software,
La Jolla, CA) was used for statistical analysis of cytokine data ap-
plying two-factor ANOVA or Student's 2-tailed t-test, when ap-
propriate. Differences with a P-value o0.05 were considered
statistically signiﬁcant.3. Results
To ﬁnd which genes were modulated by Aminaphtone in IL1β-
stimulated ECV304 endothelial cells at the transcriptional level,
we performed supervised analyses that combined an empirical
Bayesian approach and a parametric two-factor ANOVA comparing
treated vs. untreated cells at 1, 3 and 6 h, respectively (Table 1).
Two hundred and ﬁfty-two genes were found signiﬁcantly differ-
ent with an FDR o0.1 at the BETR test (Table 1 in Ref. Salazar et al.,
submitted for publication). Two-way ANOVA showed that 139 of
these genes were signiﬁcant for the treatment effect only, 47 genes
for the interaction effect only, and 66 genes for both effects. Post-
hoc comparisons identiﬁed as signiﬁcantly up- or down-regulatedrespectively 103 and 80 genes at 1 h treatment, 64 and 53 genes at
3 h, and 35 and 76 genes at 6 h, in Aminaphtone-treated vs. un-
treated ECV304 cells. Unsupervised hierarchical clustering showed
that these genes correctly discriminated between time points and
treatments (Fig. 1 in Ref. Salazar et al., submitted for publication).
Using a clustering algorithm to identify tight groups (kernels)
of highly similar elements among the 252 Aminaphtone-re-
sponsive gene transcripts, we identiﬁed ﬁve clusters of co-regu-
lated genes with different temporal patterns between Ami-
naphtone-treated and untreated cells (Fig. 1). Cluster_1 contains
83 genes that were signiﬁcantly upregulated by Aminaphtone at
all time points. Cluster_2 contains 69 genes that progressively
increase over time, but to a lesser extent in Aminaphtone-treated
cells (the net effect is a downregulation at all time points). Clus-
ter_3 contains 44 genes that progressively decrease over time, but
to a higher extent in Aminaphtone-treated cells (the net effect is a
downregulation at all time points). Cluster_4 contains 32 genes
that progressively decrease over time, but to a lesser extent in
Aminaphtone-treated cells (the net effect is an upregulation at all
time points). Cluster_5 contains 18 genes with an opposite trend
between the two treatments.
GO, KEGG, and MSigDB curated gene set comparison on the
entire dataset of differentially expressed genes showed that reg-
ulation of homeostatic and immune response processes, in-
ﬂammatory response, cytokine activity, response to hypoxia, cell
proliferation, transcription, and cell communication were sig-
niﬁcantly affected by treatments with Aminaphtone in IL-1β sti-
mulated endothelial cells (Table 2 in Ref. Salazar et al., submitted
for publication). Functional analysis of the ﬁve gene clusters with
similar expression pattern substantially conﬁrmed the aforemen-
tioned analysis and showed that the most of variation involving
stress and inﬂammatory responses (including cytokine-cytokine
receptor interaction and matrix metalloproteinases) was within
Cluster_2 (Table 2), whose genes were on average downregulated
at all time points. Consistently, Cluster_3 and Cluster_5 were en-
riched with genes involved respectively in signal transduction and
cell division, which thus turned out to be repressed.
In particular, EBI3, TNFRSF11B and TNFSF18 genes, showing a
cytokine activity, together with the EDN1, IGFL1, CCL22, and
S100A3 transcripts were found signiﬁcantly down-regulated at
each time-point treatment (see the top differentially expressed
genes in Table 1). Incubation with Aminaphtone signiﬁcantly re-
duced the IL-1β-induced transcription of a number of proin-
ﬂammatory cytokines and chemokines: i.e. several transcripts
showing a cytokine activity, such as the colony stimulating factor
2 and 3 (CSF2, CSF3), involved in macrophage differentiation, and
(C-X-C motif) chemokines and ligands, were found downregulated
early after treatment (1 or 3 h; Table 1 and see also Table 1 in Ref.
Salazar et al., submitted for publication). IL1B, IL7, MMP3, MMP10,
and TGFB2 resulted at lower expression levels at late time points,
whereas histone cluster 2 (HIST2H4A) was upregulated at all time
points.
We then performed a promoter analysis to try and ﬁnd out TFs
whose binding sites are enriched in the promoters of the clusters
of co-regulated genes identiﬁed above (Table 3). Results showed
that at least 12 binding sites are signiﬁcantly over-represented in
the set of promoters of the co-expressed gene clusters. In parti-
cular, Aminaphtone putatively inﬂuenced the regulation of gene
expression through TFs that binds to the TATA-box (the core
promoter sequence) in Cluter_2 and through 8 TFs, including zinc
ﬁnger proteins, in Cluster_3.
Microarray data were conﬁrmed by RT-qPCR on a set of six
genes, (CSF3, IGFL1, TGFB2, TNF, TNFRSF11B, and TNFSF18). RT-qPCR
and microarray analyses showed a strong correlation, as ascer-
tained by highly signiﬁcant (Po0.0001) Pearson's coefﬁcients
(Fig. 2, left column). The original dataset was validated also against
Fig. 1. Heatmaps of differentially expressed genes, as identiﬁed by the BETR algorithm, modulated by Aminaphtone (AMNA) in treated vs. untreated IL1β-stimulated
endothelial cells. The CLICK clustering algorithm identiﬁed 5 distinct gene clusters with similar expression patterns. Panels in the bottom left part of the ﬁgure show the
average expression patterns in the 5 clusters (mean 7 S. E. M. of the normalized mean-centred expression values).
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Table 2
Biological processes and pathways signiﬁcantly modulated by Aminaphtone in treated vs. untreated IL-1β stimulated endothelial cells.
Set Enriched with GO term and/or KEGG
pathway
#genes raw P corr. P Gene List
Cluster_1 interspecies interaction between
organisms
9 6.82E-06 0.0240 [ULBP3, TFRC, EFNB2, POLA1, BUB1, NXF1, GTF2B, PIK3R1, BCL2L11]
Cluster_2 cytokine activity 12 3.68E-12 0.0010 [CSF2, TNFRSF11B, CCL22, EDN1, IL1B, IL32, CD70, CXCL6, CX3CL1, TNFSF18, EBI3, BMP6]
response to decreased oxygen levels 11 1.60E-10 0.0010 [PLAT, STC2, HMOX1, EDN1, BNIP3, IL1B, OXTR, STC1, CX3CL1, MMP3, DDIT4]
immune system process 21 2.99E-09 0.0010 [CSF2, PODXL, STAT5A, FST, EDN1, BNIP3, CD70, IL32, CXCL6, CX3CL1, IL7R, TNFSF18,
MMP1, SERPINB9, CCL22, CLEC4E, TICAM1, IL1B, SELE, EBI3, BMP6]
response to wounding 17 9.13E-09 0.0010 [PLAT, STX4, CXCL6, CX3CL1, MMP3, MMP1, DDR1, TNFAIP6, CCL22, HMOX1, TICAM1,
SERPINA3, IL1B, LOX, SELE, SRGN, BMP6]
response to steroid hormone stimulus 11 1.51E-08 0.0010 [PLAT, SERPINB9, TNFRSF11B, HMOX1, EDN1, IL1B, OXTR, STC1, LOX, MMP3, HCAR1]
response to stress 26 7.76E-08 0.0010 [EDN1, BNIP3, OXTR, IL32, CXCL6, CX3CL1, MMP3, MMP1, CCL22, HMOX1, SLC2A1, TI-
CAM1, SERPINA3, IL1B, LOX, SRGN, PLAT, STX4, STC2, HILPDA, DDIT4, DDR1, TNFAIP6,
STC1, SELE, BMP6]
negative regulation of secretion 7 9.83E-08 0.0010 [HMOX1, EDN1, FST, IL1B, OXTR, CX3CL1, SRGN]
cell-cell signalling 15 1.33E-07 0.0010 [PLAT, STX4, STC2, EDN1, OXTR, HILPDA, CD70, CX3CL1, CXCL6, TNFSF18, TNFAIP6,
CCL22, GPR56, IL1B, STC1]
regulation of cytokine production 10 2.46E-07 0.0020 [CSF2, CLEC4E, STAT5A, HMOX1, TICAM1, IL1B, HILPDA, CX3CL1, EBI3, SRGN]
response to organic substance 19 1.56E-06 0.0070 [PLAT, STC2, STAT5A, EDN1, OXTR, CX3CL1, IL7R, MMP3, TNFSF18, SERPINB9, TNFRSF11B,
HMOX1, TICAM1, IL1B, STC1, LOX, SELE, EBI3, HCAR1]
response to cytokine stimulus 10 4.87E-06 0.0180 [STAT5A, EDN1, IL1B, OXTR, CX3CL1, IL7R, MMP3, TNFSF18, SELE, EBI3]
positive regulation of developmental
process
11 5.90E-06 0.0210 [CSF2, STAT5A, HMOX1, EDN1, FST, BNIP3, IL1B, OXTR, CX3CL1, IL7R, BMP6]
regulation of localization 16 6.74E-06 0.0230 [PODXL, FST, EDN1, HK2, OXTR, HILPDA, CX3CL1, MMP3, MMP10, CLEC4E, HMOX1,
SLC2A1, IL1B, SELE, SRGN, BMP6]
anti-apoptosis 7 8.58E-06 0.0300 [SERPINB9, CSF2, STAT5A, HMOX1, BNIP3, IL1B, TNFSF18]
response to external stimulus 14 8.76E-06 0.0300 [CYP24A1, STC2, STAT5A, EDN1, BNIP3, CX3CL1, CXCL6, MMP3, TNFRSF11B, CCL22,
HMOX1, SLC2A1, IL1B, STC1]
regulation of body ﬂuid levels 10 1.50E-05 0.0450 [PLAT, DDR1, STX4, STAT5A, EDN1, HK2, OXTR, CX3CL1, MMP1, SRGN]
Cytokine-cytokine receptor interaction 9 2.5E-07 0.0001 [CSF2, TNFRSF11B, CCL22, IL1B, CD70, CXCL6, CX3CL1, IL7R, TNFSF18]
Matrix Metalloproteinases 3 1.44E-04 0.0052 MMP10, MMP3, MMP1
Cluster_3 regulation of signal transduction 16 1.48E-07 0.0010 [PDGFB, EFNA1, LMCD1, ANKRD1, SPRY4, LIF, PLEKHG2, DKK1, ULK1, SYDE1, ACAP1,
TGFB1I1, PHLDA3, AGAP2, DUSP8, RASD2]
Cluster_4 response to organic substance 12 3.73E-06 0.0110 [EIF4B, FOS, CD83, CTH, EGR2, NR4A2, PTCH1, DNAJB1, IDI1, PIK3R3, BRCA1, CITED2]
negative regulation of macromolecule
biosynthetic process
9 3.81E-06 0.0120 [ELF3, ID2, PER1, PTCH1, MARCH8, PRDM1, GRB7, BRCA1, CITED2]
Cluster_5 cell division 5 1.59E-05 0.0450 [CENPF, CEP55, ECT2, ERCC6L, TGFB2]
GO: Gene Ontology; KEGG: Kyoto Encyclopaedia of Genes and Genomes; Cluster_n: gene clusters identiﬁed by the CLICK algorithm; raw P: uncorrected P-values; corr. P: P-
values corrected for multiple comparisons.
G. Salazar et al. / European Journal of Pharmacology 782 (2016) 59–6964an independent experimental series performed in triplicate, which
shown similar results both for transcripts modulated by Ami-
naphtone at all time points (CSF3, IGFL1, and TNFSF18), and for
genes modulated at late time points (TGFB2 and TNFRSF11B), or for
an unmodulated transcript such as TNF (see Table 1 and Fig. 2,
right column).
A multiplex ELISA experiment conﬁrmed and extended the
observations described above. We analysed at different time
points (3, 6, 12, and 24 h) the release of a total of 30 cytokines and
chemokines. We found that 21 out of 30 were detectable in the
supernatants. Two-way ANOVA (Table 4), followed by Bonferroni
pairwise comparison (Fig. 3), showed that 15 chemokines/cyto-
kines were signiﬁcantly modulated by Aminaphtone, namely:
CCL2 (MCP-1), CSF2 (GM-CSF), CSF3 (G-CSF), CXCL10 (IP-10), IFNA1
(IFN-α), TNF (TNF-α), IL1R1 (IL-1RA), IL-6, IL-7, IL-8, IL-10, IL-15,
EGF, FGF2 (FGF-basic), VEGFA (VEGF). All appeared to be down-
regulated except FGF2, which was upregulated at early time points
(Fig. 3).
We further extended our observations by analysing with an
immunoassay quantitative technique three additional proteins
(Fig. 4). CXCL6 and TGF-β2 production showed a down-modula-
tion with a high statistical signiﬁcance at late time points (12 and
24 h). Finally, IGF1 production was upregulated by Aminaphtone at
all time points.
Consistent with these results, most of the chemokines and
cytokines that were found downregulated at the protein level inthe supernatants (Figs. 3 and, 4) appeared to be signiﬁcantly
downregulated at the mRNA level (Table 5): i.e., CCL2, CSF2, CSF3,
CXCL6, IL-6, TGF-β2, and VEGF. In addition, IL-8 mRNA and protein
were not signiﬁcantly modulated by Aminaphtone at any time
point, even if the protein showed a trend in downregulation. On
the contrary, TNF-αwas strongly downregulated at protein but not
at mRNA level: this suggests that the drug had also post-tran-
scriptional effects. This may be the case also for IL1R1 and FGF2,
which did not show any signiﬁcant regulation at the mRNA level.
We could not perform this comparison for the other 8 cytokines,
because their signals on the microarray were too low or did not
pass the quality control criteria.4. Discussion
The main ﬁnding of this study is that Aminaphtone showed
many unexpected biological activities, which may potentially be
effective in the therapeutic management of several inﬂammatory
diseases. Previous works analysed the effects of Aminaphtone in
the treatment of CVI, which is the clinical condition the drug is
mainly used for. The results of this study showed remarkable
downregulation of an array of inﬂammatory molecules and upre-
gulation of genes protective against the inﬂammatory state. In-
deed, Aminaphtone was capable of down-regulating both at the
mRNA and the protein level the majority of molecules across the
Table 3
Promoter analysis in gene clusters modulated by Aminaphtone in treated vs. untreated IL1β-stimulated endothelial cells.
Gene set Enriched with TF
binding sites
#genes P Gene List
Cluster_1 M88819 [Rubin-10
(MTE)]
28 2.64E-04 RAI14(84,7), NCAPG(174), PRKCA(719), CYB5D1(63), VAMP1(17), CBLB(166), STK17B(79,135), ZC3HAV1
(152), GCLC(175), LPIN1(44), ZCCHC14(948), ZNF426(23), SLC33A1(153), EIF4EBP2(118), ISCA1(471),
BCL2L11(331,204,167), MERTK(444), AAK1(557,20), EFNB2(499), GCLM(246), C7orf53(313), CACHD1
(462), MKI67(109,51), OSBPL11(667,125), SERPINI1(192), GAS2L3(40), KIAA0922(186,10), PIK3R1(162)
Cluster_2 M00043 [dl] 14 9.16E-06 TICAM1(107), SLC6A14(493,127), OLFM2(385), CD70(55), DDIT4(973), CCL22(222), CXCL6(91), EBI3
(295), PLAT(500), HILPDA(393), IL1B(172), FRMD6(298), NAV3(328), SAMD4A(298)
M00216 [TATA] 11 5.25E-05 MMP3(812,162), ZC3H7B(177), MMP10(33), SELE(295,49), KRT34(373), FRMD6(779), CLEC4E(730),
NAV3(428,159), SAMD4A(52), LOX(468,421), IL7R(554)
Cluster_3 M00720 [CAC-bind-
ing protein]
21 3.14E-08 TRIP6(709,88), PDGFB(49), AGAP2(121), KCTD11(872), SPRY4(433), ANKRD1(99), SYDE1(291), EFNA1
(588), ERF(191), ZNF48(757,462), ACAP1(70), ISG20L2(104), PHLDA3(408,319), TAGLN(70), LIF
(852,618,81), NINJ1(603), ARL4C(571,477), SERPINH1(696,88,149), FBLIM1(519), BCL3
(619,608), MOB3C(881,826,339)
M00915 [AP-2] 21 4.54E-05 TRIP6(948), MEF2D(444), KCTD11(870), RASD2(494), DUSP8(682,643), SPRY4(971,518), KRT16
(343), SYDE1(184,12), EFNA1(625), ERF(687), ZNF48(152,107), ACAP1(67), UBALD1
(859,305,15), TGFB1I1(90), PHLDA3(235), NINJ1(744,86), ARL4C(187), PTP4A3(196), ENO2(232),
SERPINH1(93,39), PLEKHG2(21)
M00257 [RREB-1] 19 5.79E-05 TRIP6(880), MEF2D(162), PDGFB(911), NIPAL4(956), KCTD11(878), DKK1(610,144), KRT16(206),
SYDE1(455), EFNA1(920,113), ERF(677,483,203), ZNF48(463), ACAP1(897), TGFB1I1(241), TAGLN
(375), LIF(82), NINJ1(609), FBLIM1(545,536,525), BCL3(614), MOB3C(338,134)
M00401 [ABF1] 15 1.95E-04 TRIP6(71), MEF2D(453,439,110), PXDC1(105,114), KCTD11(468,230,142), DUSP8(698,677,661),
FRMD8(991,125,81), RASD2(712,20), EFNA1(725), ERF(69,58), ISG20L2(844,128), TGFB1I1(55,12),
ENO2(45), PTP4A3(40,176), SERPINH1(37), PLEKHG2(74)
jMA0056 [ZNF42 1–4] 35 2.95E-04 TRIP6(851,704,325,229,54), MEF2D(774,121), RASD2(988,141), KRT16
(899,448,435,339,263,55), ANKRD1(779), ERF(683,632,591,562,387), ZNF48(487),
UBALD1(302,44), TGFB1I1(5), PHLDA3(786,646), LMCD1(132), ENO2(96), PTP4A3(585,58), BCL3
(894,621,126), PXDC1(461), ULK1(751), PDGFB(434), AGAP2(687), NIPAL4(76), KCTD11(676),
C14orf105(509), DUSP8(982,821,105), DKK1(73), CXCL3(438,9), SPRY4(499), SYDE1(494,478,439),
EFNA1(83), ACAP1(54,153), TAGLN(982,776,376,349,110,65,115), LIF
(973,873,792,620,285,83,10,79), ARL4C(457,260,191), SERPINH1(415,43,154), FBLIM1
(588,402), PLEKHG2(430), MOB3C(876,706,329,125,29)
M01033 [HNF4] 28 3.95E-04 TRIP6(532), MEF2D(742,303), RASD2(379,207,117), KRT16(908,887,376), ERF
(817,504,394,282), UBALD1(819,784,675,210), ENO2(395,349,66), PTP4A3(213,194,35),
BCL3(917,686,666,499,45), PXDC1(338,264), ULK1(278), NIPAL4(117,7,96), KCTD11(900),
FRMD8(103), DUSP8(459,119), DKK1(393), CXCL3(239), SPRY4(509,96), EFNA1(77,21), ISG20L2(178),
ACAP1(875,10,68), TAGLN(337), LIF(355,330), NINJ1(612,50), ARL4C(783,736,416,334),
FBLIM1(635), SERPINH1(165), MOB3C(109,24)
M01122 [ZNF219] 19 4.40E-04 PXDC1(823,812,645), MEF2D(578,12), PDGFB(189), DUSP8(521), SPRY4(856,431), KRT16(989),
EFNA1(49), ERF(195,38), ZNF48(460,347), ISG20L2(490), UBALD1(366), TGFB1I1(63), LIF(75), NINJ1
(538), LMCD1(726), FBLIM1(285), PLEKHG2(26), BCL3(606), MOB3C(886)
M00002 [E47] 14 4.89E-04 PXDC1(777,715), KCTD11(339), RASD2(327), SPRY4(338), KRT16(924), ANKRD1(101), EFNA1(835),
ERF(699,513), PHLDA3(377), CEBPD(738), NINJ1(663), LMCD1(94), ARL4C(931), FBLIM1(44)
Cluster_4 M00725 [HP1 site
factor]
7 3.51E-04 PRDM1(540), EGR2(168), NR4A2(613), BRCA1(605,455), MARCH8(132), ELOVL6(921), GLCCI1
(941,755)
TF: transcription factor; binding sites, in square brackets, are identiﬁed by their BIOBASE accession number.
MTE: motif ten element; dl: dorsal; Ap-2: activating protein 2; RREB1: RAS-responsive element binding protein 1; ABF1: activated B cell factor-1; ZNF42: zinc ﬁnger protein
42; HNF4: hepatocyte nuclear factor 4; ZNF219: zinc ﬁnger protein 219; HP1: heterochromatin protein 1.
The gene lists contain the position of the TF binding site for a given gene.
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Likewise, we documented an upregulation of an antiinﬂammatory
factor such as IGF1.
Aminaphtone appeared also able to favourably modulate im-
mune response genes (down-regulating cytokine biosynthesis,
transcripts involved in lymphocyte differentiation and cell pro-
liferation, and cytokine-cytokine receptor interaction) and to reg-
ulate genes engaged in homeostasis, secretion, body ﬂuid levels,
response to hypoxia, cell division, and cell-to-cell communication
and signalling. Results were conﬁrmed and extended analysing the
secretome of endothelial cells at different time points after sti-
mulation with IL-1β, showing signiﬁcant reduction of the release
of 14 cytokines and chemokines. Most of these latter effects were
conﬁrmed at the transcriptional level. Conversely, some effects, in
particular the downregulation of TN-α, appeared to be at post-
transcriptional level, thus indicating that the drug may act at
multiple stages.Using graph-theoretic and statistical techniques, we identiﬁed
ﬁve clusters of highly similar expressed genes. Assuming that
genes co-expressed over multiple time points are regulated by
common TFs, and therefore are expected to share common reg-
ulatory elements in their promoters, we identiﬁed TFs whose
binding sites are signiﬁcantly over-represented in those gene
clusters, based on known models for TF binding sites. Using this
approach, we predicted several TFs as highly signiﬁcant candidate
regulators of the corresponding set of Aminaphtone-responsive
genes. The picture that emerges is very complex and may include
interactions with TFs involved in angiogenesis, such as zinc ﬁnger
proteins (Hamik et al., 2006), in cell cycle, such as the basic helix-
loop-helix TF E47 (Kim et al., 2015), and in proliferation and dif-
ferentiation, such as AP-2 (Eckert et al., 2005). Interestingly, pro-
moters of genes in Cluster_2 are enriched with binding sites for
Dorsal, a Rel-protein with activator/repressor functions that is the
Drosophila homolog of mammalian NF-κB (Mrinal et al., 2011),
Table 4
Chemokines and cytokines modulated by Aminaphtone in treated vs. untreated IL1β-stimulated endothelial cells.
Source of Variation CCL2 CSF2 CSF3 CXCL10 IFN-α TNF-α IL-1RA IL-6 IL-7 IL-8 IL-10 IL-15 EGF FGF2 VEGF
P-value Interaction 0.0061 o0.0001 o0.0001 0.0371 0.2073 0.0067 0.0454 0.4474 0.0975 0.8389 0.9927 0.1957 0.1709 0.0221 0.2566
Drug o0.0001 o0.0001 o0.0001 o0.0001 o0.0001 o0.0001 0.0092 0.0004 0.0009 0.0238 0.0022 0.0002 0.0100 0.0439 0.0024
Time o0.0001 o0.0001 o0.0001 0.0003 o0.0001 0.0001 o0.0001 o0.0001 0.0003 o0.0001 0.0311 o0.0001 0.0073 o0.0001 o0.0001
% total variance Interaction 6.47 5.87 4.33 7.02 1.37 9.89 4.50 1.70 8.12 0.60 0.16 2.37 7.38 5.81 3.47
Drug 21.85 16.47 9.84 55.71 8.13 39.95 4.73 9.67 15.39 3.95 19.49 8.34 15.00 2.19 8.86
Time 53.61 75.03 80.27 27.66 78.96 22.11 81.21 71.28 28.83 70.77 17.73 70.04 23.23 84.68 57.79


























































































Fig. 3. Multiplex cytokine/chemokine analysis of the secretome of Aminaphtone-treated vs. untreated IL1β-stimulated endothelial cells (n¼6 for each treatment). * Po0.05,
** Po0.01, *** Po0.001.
G. Salazar et al. / European Journal of Pharmacology 782 (2016) 59–69 67and with TATA-box DNA sequence, which is bound by a number of
TFs to make up the RNA polymerase II preinitiation complex (Lee
and Young, 2000): these TFs have both been shown to interact
with several inﬂammatory and immune regulators. Further studiesare needed to dissect the molecular mechanism of action of
Aminaphtone.
Focussing our attention on inﬂammation-related genes, the
effect of Aminaphtone appears as a substantial and coordinated
Fig. 4. ELISA analysis of CXCL6, IGF-1, and TGF-β2 release by Aminaphtone-treated
vs. untreated IL1β-stimulated endothelial cells (n¼6 for each treatment). * Po0.05,
** Po0.01, *** Po0.001.
G. Salazar et al. / European Journal of Pharmacology 782 (2016) 59–6968inﬂuence on the inﬂammatory state of the endothelial cells sti-
mulated by IL1β, which can be divided in several phases: (1) early
and sustained downregulation of vasoactive and inﬂammatoryTable 5
Difference in expression at the mRNA level of chemokines and cytokines modulated by
Fold
Symbol Name 1 h
CCL2 chemokine (C-C motif) ligand 2 1.
CSF2 colony stimulating factor 2 (granulocyte-macrophage) 1.
CSF3 colony stimulating factor 3 (granulocyte) 1.
CXCL6 chemokine (C-X-C motif) ligand 6 1.
FGF2 ﬁbroblast growth factor 2 (basic) 1.
IL1R1 interleukin 1 receptor, type I 1.
IL6 interleukin 6 (interferon, beta 2) 1.
IL8 interleukin 8 1.
TGFB2 transforming growth factor, beta 2 1.
TNF tumor necrosis factor 1.
VEGFA vascular endothelial growth factor A 1.
Pairwise signiﬁcant: signiﬁcance level for pairwise comparisons: a Po0.05; b Po0.01.genes (EDN1, HMOX1, EBI3, and TRAF1), consistent with our pre-
vious observations (Scorza et al., 2008a). In particular, EBI3 en-
codes a secreted that heterodimerizes with a 28 kDa protein to
form interleukin 27, a cytokine that regulates T cell and in-
ﬂammatory responses in part by activating the Jak/STAT pathway.
(2) Early but transient downregulation of inﬂammatory factors
(SERPINA3, PDGFB, CXCL3) and the stress-response nuclear re-
ceptor NR4A2. Dysregulation of the latter gene has been associated
with rheumatoid arthritis (Smith, 2001). (3) A late downregulation
of AREG, a member of the epidermal growth factor family, and a
late downregulation of IL1β, and the matrix metallopeptidase
MMP3. The protein encoded by AREG interacts with the EGF/TGF-
α receptor to promote the growth of normal epithelial cells and is
associated with a psoriasis-like skin phenotype (Pereira de Godoy,
2008). (4) An early and sustained upregulation of PRKCA, a kinase
that plays roles in many different cellular processes, such as cell
adhesion, cell transformation, cell cycle checkpoint, and cell vo-
lume control, as well as vasoreactivity (de Godoy and Batigalia,
2009). (5) Early but transient upregulation of CD83, BRCA1, and of
the transcription factor FOS. Reduced expression of FOS has been
associated to impaired vasculogenesis (Hamik et al., 2006).
These ﬁndings are particularly intriguing, because of the pos-
sible use of this drug in diseases where cytokine activation, va-
soconstriction, ﬁbrosis, and endothelial damage play a central role.
This observation prompts for further studies aimed at investigat-
ing whether Aminaphtone may act like a broad spectrum anti-
inﬂammatory drug.
Noteworthy effects of Aminaphtone are those on TGF-β2,
CXCL6, and IGF-1 release. TGFβ2 is one of the main molecules
active in inﬂammatory mechanism with a role in ﬁbrotic process.
In particular its production is very increased in patients with
systemic sclerosis (Falanga et al., 1992; Hasegawa et al., 2004;
Leask, 2006). In this light, the decrement of its release by IL1β-
stimulated endothelial cells lately after treatment with Ami-
naphtone appears of great importance. CXCL-6 is a chemotactic
factor (Wuyts et al., 2003) involved in the neutrophil recruitment
in the site of venous ulcer in CVI. The signiﬁcant down-regulation
of its mRNA and protein release induced by Aminaphtone may, at
least in part, explain the drug effectiveness in this pathologic
condition. IGF-1, the insulin growth factor 1, exerts pleiotropic
antioxidant and anti-inﬂammatory effects, which together may
reduce atherosclerotic burden and vascular injury (Shai et al.,
2011), and has a protective role in the pulmonary ﬁbrotic process.
High IGF-1 levels are, in fact, dosed in patients affected by idio-
pathic pulmonary ﬁbrosis and are correlated with a better healing
because of its property in the induction of epithelialization repair
in post-inﬂammation tissue (Krein and Winston, 2002; Muguerza
et al., 2001). Thus, IGF-1 up-regulation induced by AminaphtoneAminaphtone in treated vs. untreated IL1β-stimulated endothelial cells.
-change Pairwise signiﬁcant
3 h 6 h 1 h 3 h 6 h
5 1.1 1.1 a
7 1.9 1.5 a b
2 1.4 1.2 a
4 1.3 1.6 a a b
3 1.3 1.1
7 1.5 1.4
4 1.3 1.1 a
0 1.1 1.1
2 2.1 1.5 b a
2 1.2 1.3
2 1.3 1.4 a
G. Salazar et al. / European Journal of Pharmacology 782 (2016) 59–69 69could have a therapeutic role in many inﬂammatory disorders, as
it is shown to be a protective anti-ﬁbrotic factor.
As a matter of speculation, it is therefore possible to imagine a
role of Aminaphtone in the treatment of those clinical conditions
in which the endothelial damage is a key event and/or precedes all
other manifestations. An example of this is systemic sclerosis, a
disease in which molecules like TGF-β and several other in-
ﬂammatory proteins are strongly involved (Gruschwitz et al.,
1990). Another example is pulmonary hypertension, which re-
mains one of the most terrible complications of systemic sclerosis,
in which a key role is exerted by endothelin-1 (Chester and Ya-
coub, 2014; Santaniello et al., 2006). Finally, another paramount
example is atherosclerosis and related conditions, of which the
endothelial dysfunction is an early marker (Davignon and Ganz,
2004). The underlying idea is to use Aminaphtone as a novel
treatment in pathologies in which chronic inﬂammatory state and
endothelium dysfunction are the main pathogenic features.Financial support
The work was entirely supported by internal funds from the
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Mi-
lano, Italy. The drug was kindly provided by Laboratori Baldacci S.
p. A. (Via S. Michele degli Scalzi, 73, 56124 Pisa, Italy), which had
no part in the study design, data analysis, and drafting of the
present manuscript.Acknowledgments
The authors gratefully acknowledge Elena Grovetti (Depart-
ment of Pathophysiology and Transplantation, Università degli
Studi di Milano) for excellent technical assistance.References
Andersen, C.L., Jensen, J.L., Orntoft, T.F., 2004. Normalization of real-time quanti-
tative reverse transcription-PCR data: a model-based variance estimation ap-
proach to identify genes suited for normalization, applied to bladder and colon
cancer data sets. Cancer Res. 64, 5245–5250.
Aryee, M.J., Gutierrez-Pabello, J.A., Kramnik, I., Maiti, T., Quackenbush, J., 2009. An
improved empirical bayes approach to estimating differential gene expression
in microarray time-course data: BETR (Bayesian Estimation of Temporal Reg-
ulation). BMC Bioinforma. 10, 409.
Bolstad, B.M., Irizarry, R.A., Astrand, M., Speed, T.P., 2003. A comparison of nor-
malization methods for high density oligonucleotide array data based on var-
iance and bias. Bioinformatics 19, 185–193.
Chester, A.H., Yacoub, M.H., 2014. The role of endothelin-1 in pulmonary arterial
hypertension. Glob. Cardiol. Sci. Pract. 2014, 62–78.
Davignon, J., Ganz, P., 2004. Role of endothelial dysfunction in atherosclerosis.
Circulation 109, III27–32.
Doni, A., Mondaini, F., Somigli, M., Comparini, L., Gavazzi, M., Ventimiglia, V., 1983.
Modiﬁcation of primary hemostasis and capillary fragility induced by ami-
naftone in chronic renal insufﬁciency. Clin. Ter. 107, 45–50.
Eckert, D., Buhl, S., Weber, S., Jager, R., Schorle, H., 2005. The AP-2 family of tran-
scription factors. Genome Biol. 6, 246.
Falanga, V., Gerhardt, C.O., Dasch, J.R., Takehara, K., Ksander, G.A., 1992. Skin dis-
tribution and differential expression of transforming growth factor beta 1 and
beta 2. J. Dermatol. Sci. 3, 131–136.
Gentleman, R.C., Carey, V.J., Bates, D.M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B.,
Gautier, L., Ge, Y., Gentry, J., Hornik, K., Hothorn, T., Huber, W., Iacus, S., Irizarry,
R., Leisch, F., Li, C., Maechler, M., Rossini, A.J., Sawitzki, G., Smith, C., Smyth, G.,
Tierney, L., Yang, J.Y., Zhang, J., 2004. Bioconductor: open software development
for computational biology and bioinformatics. Genome Biol. 5, R80.
Giaid, A., Yanagisawa, M., Langleben, D., Michel, R.P., Levy, R., Shennib, H., Kimura,
S., Masaki, T., Duguid, W.P., Stewart, D.J., 1993. Expression of endothelin-1 in the
lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328,
1732–1739.de Godoy, J.M., Batigalia, F., 2009. Aminaphtone in the control of Schamberg’s
disease. Thromb. J. 7, 8.
Gruschwitz, M., Muller, P.U., Sepp, N., Hofer, E., Fontana, A., Wick, G., 1990. Tran-
scription and expression of transforming growth factor type beta in the skin of
progressive systemic sclerosis: a mediator of ﬁbrosis? J. Invest. Dermatol. 94,
197–203.
Hamik, A., Wang, B., Jain, M.K., 2006. Transcriptional regulators of angiogenesis.
Arterioscler. Thromb. Vasc. Biol. 26, 1936–1947.
Hasegawa, M., Sato, S., Takehara, K., 2004. Augmented production of transforming
growth factor-beta by cultured peripheral blood mononuclear cells from pa-
tients with systemic sclerosis. Arch. Dermatol. Res. 296, 89–93.
Irizarry, R.A., Hobbs, B., Collin, F., Beazer-Barclay, Y.D., Antonellis, K.J., Scherf, U.,
Speed, T.P., 2003. Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostatistics 4, 249–264.
Kim, S., Lahmy, R., Riha, C., Yang, C., Jakubison, B.L., van Niekerk, J., Staub, C., Wu, Y.,
Gates, K., Dong, D.S., Konieczny, S.F., Itkin-Ansari, P., 2015. The basic helix-loop-
helix transcription factor E47 reprograms human pancreatic cancer cells to a
quiescent acinar state with reduced tumorigenic potential. Pancreas 44,
718–727.
Krein, P.M., Winston, B.W., 2002. Roles for insulin-like growth factor I and trans-
forming growth factor-beta in ﬁbrotic lung disease. Chest 122, 289S–293S.
Leask, A., 2006. Scar wars: is TGFbeta the phantom menace in scleroderma? Ar-
thritis Res. Ther. 8, 213.
Lee, T.I., Young, R.A., 2000. Transcription of eukaryotic protein-coding genes. Annu.
Rev. Genet. 34, 77–137.
Mrinal, N., Tomar, A., Nagaraju, J., 2011. Role of sequence encoded kappaB DNA
geometry in gene regulation by Dorsal. Nucleic Acids Res. 39, 9574–9591.
Muguerza, B., Castilla-Cortazar, I., Garcia, M., Quiroga, J., Santidrian, S., Prieto, J.,
2001. Antiﬁbrogenic effect in vivo of low doses of insulin-like growth factor-I in
cirrhotic rats. Biochim. Biophys. Acta 1536, 185–195.
Pereira de Godoy, J.M., 2008. Aminaphtone in idiopathic cyclic oedema syndrome.
Phlebology 23, 118–119.
Pfafﬂ, M.W., 2001. A new mathematical model for relative quantiﬁcation in real-
time RT-PCR. Nucleic Acids Res. 29, e45.
Saeed, A.I., Sharov, V., White, J., Li, J., Liang, W., Bhagabati, N., Braisted, J., Klapa, M.,
Currier, T., Thiagarajan, M., Sturn, A., Snufﬁn, M., Rezantsev, A., Popov, D.,
Ryltsov, A., Kostukovich, E., Borisovsky, I., Liu, Z., Vinsavich, A., Trush, V.,
Quackenbush, J., 2003. TM4: a free, open-source system for microarray data
management and analysis. Biotechniques 34, 374–378.
Salazar, G., Bellocchi, C., Todoerti, K., Saporiti, F., Piacentini, L., Scorza, R., Colombo,
G.I., 2016. Time-course gene expression data on the transcriptional effects of
Aminaphtone on ECV304 endothelial cells. Data Brief. (submitted for
publication)
Santaniello, A., Salazar, G., Lenna, S., Antonioli, R., Colombo, G., Beretta, L., Scorza, R.,
2006. HLA-B35 upregulates the production of endothelin-1 in HLA-transfected
cells: a possible pathogenetic role in pulmonary hypertension. Tissue Antigens
68, 239–244.
Scorza, R., Santaniello, A., Salazar, G., Lenna, S., Colombo, G., Turcatti, F., Beretta, L.,
2008a. Aminaftone, a derivative of 4-aminobenzoic acid, downregulates en-
dothelin-1 production in ECV304 Cells: an in vitro Study. Drugs R. D. 9, 251–257.
Scorza, R., Santaniello, A., Salazar, G., Lenna, S., Della Bella, S., Antonioli, R., Tous-
soun, K., Beretta, L., 2008b. Effects of aminaftone 75 mg TID on soluble adhesion
molecules: a 12-week, randomized, open-label pilot study in patients with
systemic sclerosis. Clin. Ther. 30, 924–929.
Shai, S.Y., Sukhanov, S., Higashi, Y., Vaughn, C., Rosen, C.J., Delafontaine, P., 2011.
Low circulating insulin-like growth factor I increases atherosclerosis in ApoE-
deﬁcient mice. Am. J. Physiol. Heart Circ. Physiol. 300, H1898–H1906.
Sharan, R., Maron-Katz, A., Shamir, R., 2003. CLICK and EXPANDER: a system for
clustering and visualizing gene expression data. Bioinformatics 19, 1787–1799.
Smith, P.D., 2001. Update on chronic-venous-insufﬁciency-induced inﬂammatory
processes. Angiology 52 (Suppl. 1), S35–S42.
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A.,
Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., Mesirov, J.P., 2005. Gene
Set enrichment Analysis: A Knowledge-based Approach for interpreting Gen-
ome-Wide Expression proﬁles. Proc. Natl. Acad. Sci. U. S. A. 102, 15545–15550.
Supek, F., Bosnjak, M., Skunca, N., Smuc, T., 2011. REVIGO summarizes and visua-
lizes long lists of gene ontology terms. PLoS One. 6, e21800.
The Gene Ontology Consortium, 2015. Gene Ontology Consortium: going forward.
Nucleic Acids Res. 43, D1049–D1056.
Villaverde, C.A., Hernandez, R., Santolaya, C., 1989. Vascular Permeability Mod-
iﬁcation by aminaftone. Rev. Pharmacol. Clin. Exp. 6, 9–14.
Wingender, E., 2008. The TRANSFAC project as an example of framework tech-
nology that supports the analysis of genomic regulation. Brief Bioinform. 9,
326–332.
Wuyts, A., Struyf, S., Gijsbers, K., Schutyser, E., Put, W., Conings, R., Lenaerts, J.P.,
Geboes, K., Opdenakker, G., Menten, P., Proost, P., Van Damme, J., 2003. The CXC
chemokine GCP-2/CXCL6 is predominantly induced in mesenchymal cells by
interleukin-1beta and is down-regulated by interferon-gamma: comparison
with interleukin-8/CXCL8. Lab. Invest. 83, 23–34.
Zambelli, V., Santaniello, A., Fumagalli, F., Masson, S., Scorza, R., Beretta, L., Latini, R.,
2011. Efﬁcacy of aminaftone in a rat model of monocrotaline-induced pul-
monary hypertension. Eur. J. Pharmacol. 667, 287–291.
